Revolution Medicines, Inc. Financial Ratios — RVMD Stock

Profitability (USD)

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Assets (%)	- -	-45.02	-24.37	-27.45	-28.66	-32.09	-30.37	-25.98	-46.06
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Gross Margin (%)	- -	100	100	100	100	100	100	- -	- -
EBITDA Margin (%)	- -	-191.25	-101.47	-242.31	-614.75	-702.72	-4,126.74	- -	- -
Operating Margin (%)	- -	-200	-108.15	-257.54	-639.7	-730.01	-4,207.12	- -	- -
Incremental Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	1,747.31	- -
Pretax Margin (%)	- -	-207.24	-103.99	-252.5	-636.58	-704.14	-3,798.71	- -	- -
Profit Margin (%)	- -	-207.24	-95.25	-251.63	-636.58	-702.95	-3,768.28	- -	- -
Net Income to Common Margin (%)	- -	-242.1	-123.7	-256.79	-636.58	-702.95	-3,768.28	- -	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	10.79	14.4	23	2.01	- -	- -	- -	- -	- -
Sustainable Growth Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -

Credit (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Total Debt	- -	- -	- -	33	67	64	88	136	159
ST Debt	- -	- -	- -	4	6	7	7	13	16
LT Debt	- -	- -	- -	29	60	57	81	123	142
Total Debt/EBITDA	- -	- -	- -	-0.31	-0.37	-0.26	-0.18	-0.2	-0.14
Net Debt/EBITDA	0.3	1.8	0.33	1	0.6	0.65	1.46	0.8	0.33
Total Debt/EBIT	- -	- -	- -	-0.3	-0.35	-0.25	-0.18	-0.2	-0.13
Net Debt/EBIT	0.29	1.73	0.31	0.94	0.58	0.62	1.43	0.79	0.32
EBITDA to Interest Expense	-290.69	-332.46	-479.04	-1,466.93	-15,056.33	- -	- -	- -	-48.11
EBITDA-CapEx/Interest Expense	-305.98	-345.38	-503.46	-1,508.24	-15,600.33	- -	- -	- -	-48.77
EBIT to Interest Expense	-302.22	-347.66	-510.57	-1,559.11	-15,667.33	- -	-1,607.87	- -	-48.8
Interest Expense	- -	- -	- -	- -	- -	- -	- -	- -	24
Common Equity/Total Assets	-450.57	-64.32	-71.37	-46.8	-61.33	-86.38	-55.18	-67.93	-121.85
Long-Term Debt/Equity (%)	- -	- -	- -	6.11	10.03	8.38	4.41	5.43	8.72
Long-Term Debt/Capital (%)	- -	- -	- -	-12.45	-15.65	-9.01	-7.68	-7.68	-5.25
Long-Term Debt/Total Assets (%)	- -	- -	- -	5.11	8.19	7.07	3.91	4.81	6.04
Total Debt/Equity (%)	- -	0.15	0.11	6.88	11.06	9.37	4.82	6	9.73
Total Debt/Capital (%)	- -	0.15	0.12	-14.03	-17.26	-10.08	-8.38	-8.48	-5.86
Total Debt/Total Assets (%)	- -	0.09	0.08	5.76	9.03	7.91	4.27	5.31	6.74
Net Debt to Equity	-200.38	-71.99	-10.92	-21.97	-18.01	-23.56	-38.12	-23.97	-23.52
Net Debt/Capital (%)	190.58	-268.46	-12.69	30.93	21.94	20.21	39.87	25.32	12.4
EBITDA	-30	-39	-51	-104	-181	-249	-478	-678	-1,166
EBITDA-CapEx	-32	-40	-53	-107	-187	-259	-486	-688	-1,182
Operating Income (Loss)	-31	-40	-54	-111	-188	-258	-487	-690	-1,182

Liquidity (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Cash Ratio	1.19	2.28	2.85	9.34	9.56	10.4	12.88	13.97	6.97
Current Ratio	1.24	2.8	3.11	9.63	9.77	10.65	13.06	14.2	7.14
Quick Ratio	1.19	2.52	3.05	9.48	9.66	10.48	12.89	13.97	6.97
CFO/Avg Current Liab	- -	0.06	-1.35	-2.22	-2.74	-3.67	-3.41	-3.62	-3.95
Common Equity/Total Assets	-450.57	-64.32	-71.37	-46.8	-61.33	-86.38	-55.18	-67.93	-121.85
Long-Term Debt/Equity (%)	- -	- -	- -	6.11	10.03	8.38	4.41	5.43	8.72
Long-Term Debt/Capital (%)	- -	- -	- -	-12.45	-15.65	-9.01	-7.68	-7.68	-5.25
Long-Term Debt/Total Assets (%)	- -	- -	- -	5.11	8.19	7.07	3.91	4.81	6.04
Total Debt/Equity (%)	- -	0.15	0.11	6.88	11.06	9.37	4.82	6	9.73
Total Debt/Capital (%)	- -	0.15	0.12	-14.03	-17.26	-10.08	-8.38	-8.48	-5.86
Total Debt/Total Assets (%)	- -	0.09	0.08	5.76	9.03	7.91	4.27	5.31	6.74
CFO/Total Liabilities	-238.46	1.64	-72.97	-107.91	-108.68	-177.05	-148.86	-190.19	-124.13
CFO/CapEx	-15.97	0.81	-19.16	-34.12	-22.55	-20.75	-45.36	-54.08	-56.14
Altman's Z-Score	-12.97	-2.16	-1.67	13.64	7.23	7.63	7.71	14.17	10.03

Working Capital (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Accounts Receivable Turnover	- -	5.52	6.24	5.68	4.77	6.67	3.91	- -	- -
Days Sales Outstanding	- -	66.09	58.5	64.24	76.51	54.69	93.41	- -	- -
Inventory Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory to Cash Days	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -
Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -

Enterprise Value (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Market Capitalization	- -	- -	- -	2,172	1,833	1,921	3,245	7,337	15,144
- Cash & Cash Equivalents	9	70	17	104	108	161	696	543	384
+ Preferred Equity and Hybrid Capital	72	205	305	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Total Debt	- -	- -	- -	33	67	64	88	136	159
Enterprise Value	63	136	183	1,764	1,322	1,340	1,480	5,183	13,277
Total Capital	4	96	148	-233	-386	-637	-1,050	-1,602	-2,710
Total Debt/Capital (%)	- -	0.15	0.12	-14.03	-17.26	-10.08	-8.38	-8.48	-5.86
Total Debt / EV	- -	- -	- -	0.02	0.05	0.05	0.06	0.03	0.01
EV/Sales	- -	6.73	3.65	41.05	44.98	37.87	127.82	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	102.06	- -	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	47.96	- -	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	- -	2,172	1,833	1,921	3,245	7,337	15,144
Diluted Enterprise Value	63	136	289	2,101	1,791	1,823	2,637	6,930	14,919
EV per Share	1.73	3.72	3.45	32.15	18.16	16.62	13.08	30.9	69.83
TTM Sales	- -	20	50	43	29	35	12	- -	- -
TTM EBITDA	-30	-39	-51	-104	-181	-249	-478	-678	-1,166
TTM Operating Income	-31	-40	-54	-111	-188	-258	-487	-690	-1,182
TTM Cash Flow to Firm	-25	1	-50	-100	-147	-224	-351	-557	-874
TTM Free Cash Flow to Firm	-23	3	-47	-97	-141	-214	-343	-547	-858

Multiples (USD)

API Chat

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Price/Free Cash Flow	- -	- -	- -	-22.37	-13.03	-8.99	-9.47	-13.41	-17.17
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value	63	136	183	1,764	1,322	1,340	1,480	5,183	13,277
Low Price	- -	- -	- -	17.34	21.78	14.08	15.44	25.93	29.17
EV/Sales	- -	6.73	3.65	41.05	44.98	37.87	127.82	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings Average	- -	- -	- -	-15.97	-13.28	-6.85	-6.67	-11.29	-7.74
Price/Earnings High	- -	- -	- -	-23.78	-21.86	-8.91	-9.23	-17.44	-13.78
Price/Earnings Low	- -	- -	- -	-8.62	-8.47	-4.56	-4	-7.25	-4.9
Price/Book Value	- -	- -	- -	-8.18	-4.05	-2.74	-2.85	-4.22	-5.28
Price/Book Value Average	- -	- -	- -	-6.64	-5.49	-2.43	-2.56	-3.9	-3.05
Price/Book Value High	- -	- -	- -	-9.88	-9.04	-3.16	-3.54	-6.02	-5.43
Price/Book Value Low	- -	- -	- -	-3.58	-3.5	-1.62	-1.54	-2.5	-1.93
Price/Tangible Book Value	- -	- -	- -	5.44	3.47	3.14	1.85	3.34	9.7
Price/Tangible Book Value Average	- -	- -	- -	4.42	4.71	2.78	1.66	3.09	5.61
Price/Tangible Book Value High	- -	- -	- -	6.58	7.75	3.62	2.3	4.77	9.98
Price/Tangible Book Value Low	- -	- -	- -	2.38	3	1.86	1	1.98	3.55
Price/Sales	- -	- -	- -	50.54	62.35	54.28	280.24	- -	- -
Price/Sales Average	- -	- -	- -	41.02	84.55	48.14	251.32	- -	- -
Price/Sales High	- -	- -	- -	61.06	139.17	62.65	347.85	- -	- -
Price/Sales Low	- -	- -	- -	22.14	53.95	32.09	150.87	- -	- -
Price/Cash Flow	- -	- -	- -	-21.71	-12.45	-8.56	-9.26	-13.16	-16.87
Price/Cash Flow Average	- -	- -	- -	-17.62	-16.88	-7.59	-8.3	-12.16	-9.76
Price/Cash Flow High	- -	- -	- -	-26.23	-27.79	-9.88	-11.49	-18.78	-17.36
Price/Cash Flow Low	- -	- -	- -	-9.51	-10.77	-5.06	-4.98	-7.8	-6.18
Price/Free Cash Flow Average	- -	- -	- -	-18.15	-17.67	-7.97	-8.49	-12.38	-9.94
Price/Free Cash Flow High	- -	- -	- -	-27.02	-29.08	-10.38	-11.75	-19.13	-17.67
Price/Free Cash Flow Low	- -	- -	- -	-9.8	-11.27	-5.32	-5.1	-7.95	-6.29
EV/Sales Average	- -	6.73	5.77	39.35	83.12	45.39	198.8	- -	- -
EV/Sales High	- -	6.73	5.77	59.4	137.75	59.9	295.33	- -	- -
EV/Sales Low	- -	6.73	5.77	20.48	52.52	29.34	98.35	- -	- -
EV/EBITDA Average	-2.11	-3.52	-5.68	-16.24	-13.52	-6.46	-4.82	-9.4	-7.32
EV/EBITDA High	-2.11	-3.52	-5.68	-24.51	-22.41	-8.52	-7.16	-14.84	-13.18
EV/EBITDA Low	-2.11	-3.52	-5.68	-8.45	-8.54	-4.18	-2.38	-5.82	-4.56
EV/EBIT Average	-2.03	-3.36	-5.33	-15.28	-12.99	-6.22	-4.73	-9.24	-7.22
EV/EBIT High	-2.03	-3.36	-5.33	-23.06	-21.53	-8.21	-7.02	-14.59	-12.99
EV/EBIT Low	-2.03	-3.36	-5.33	-7.95	-8.21	-4.02	-2.34	-5.72	-4.5
Last Price	- -	- -	- -	39.59	25.17	23.82	28.68	43.74	79.65
High Price	- -	- -	- -	47.83	56.18	27.49	35.6	62.4	81.97
Enterprise Value Average	63	136	289	1,692	2,443	1,606	2,302	6,368	8,536
Enterprise Value High	63	136	289	2,553	4,048	2,119	3,420	10,060	15,360
Enterprise Value Low	63	136	289	880	1,544	1,038	1,139	3,942	5,321

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
Shares Outstanding	53	53	53	67	74	90	165	186	197
Diluted Weighted Avg Shares	36	36	53	55	73	81	113	168	190
Basic Weighted Avg Shares	36	36	53	55	73	81	113	168	190
Revenue per Share	- -	0.55	0.95	0.78	0.4	0.44	0.1	- -	- -
EBITDA per Share	-0.82	-1.06	-0.96	-1.9	-2.48	-3.08	-4.22	-4.04	-6.13
Operating Income per Share	-0.85	-1.11	-1.02	-2.02	-2.58	-3.2	-4.31	-4.11	-6.22
Basic EPS, GAAP	-0.96	-1.34	-1.17	-2.01	-2.57	-3.08	-3.86	-3.58	-5.95
Basic EPS from Cont Ops	-0.85	-1.15	-0.9	-1.97	-2.57	-3.08	-3.86	-3.58	-5.95
Diluted EPS, GAAP	-0.96	-1.34	-1.17	-2.01	-2.57	-3.08	-3.86	-3.58	-5.95
Diluted EPS from Cont Ops	-0.85	-1.15	-0.9	-1.97	-2.57	-3.08	-3.86	-3.58	-5.95
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Flow per Share	-0.69	0.03	-0.94	-1.82	-2.02	-2.78	-3.1	-3.32	-4.72
Free Cash Flow per Basic Share	-0.73	-0.01	-0.99	-1.88	-2.11	-2.92	-3.17	-3.38	-4.81
Cash & Equivalents per Share	0.25	1.91	2.32	8.03	7.93	8	16.38	13.65	10.65
Book Value per Share	-1.86	-3.01	-2.98	-4.84	-6.22	-8.7	-10.05	-10.36	-15.09
Tangible Book Value per Share	-1.86	-5.1	-4.33	7.27	7.25	7.59	15.5	13.08	8.21

Revolution Medicines, Inc.

Profitability (USD)

Credit (USD)

Liquidity (USD)

Working Capital (USD)

Enterprise Value (USD)

Multiples (USD)

Per Share Data Items (USD)